Novartis undertook several initiatives to educate doctors and patients about osteonecrosis of the jaw (ONJ) associated with their drug Zometa, including: 1) Sending a "Dear Doctor" letter to hematologists/oncologists and oral surgeons informing them of ONJ; 2) Updating promotional materials to include information about ONJ; 3) Meeting with nine patient advocacy groups to discuss ONJ; and 4) Developing a patient brochure and white paper about dental health and ONJ for cancer patients taking Zometa.

3. Patient Brochure (NS21-1) “Taking Care of Yourself While Living With Cancer: Dental Health and Osteonecrosis of the Jaw” Novartis Patient Information Brochure. 2004.

4. Novartis Initiatives—Patient Education

5. ONJ White Paper (NS21-1) “Taking Care of Yourself While Living With Cancer: Dental Health and Osteonecrosis of the Jaw” Novartis Patient Information Brochure. 2004.